|Bid||9.50 x 1800|
|Ask||18.23 x 800|
|Day's Range||10.20 - 10.69|
|52 Week Range||5.97 - 54.84|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||10.83|
CAMBRIDGE, Mass., March 13, 2019 -- Solid Biosciences Inc. (NASDAQ: SLDB) today reported financial results for the fourth quarter and fiscal year ended December 31, 2018 and.
The Zacks Analyst Blog Highlights: Spark Therapeutics, Solid Biosciences, REGENXBIO, Editas Medicine and uniQure
Roche Holdings AG Basel ADR (OTC: RHHBY )'s announcement regarding an agreement to acquire gene therapy company Spark Therapeutics Inc (NASDAQ: ONCE ) has sparked a rally in the latter's shares. The Analysts ...
NEW YORK , Feb. 20, 2019 /PRNewswire/ -- Bristow Group Inc. (BRS) Lifshitz & Miller announces investigation into possible securities laws violations in connection with the Company disclosing that it "did ...
FDA accepts Sarepta's (SRPT) regulatory application seeking approval for DMD therapy, golodirsen, and grants priority review. A decision is expected in August 2019.
Why Solid Biosciences Stock Nosedived 67.82% YesterdayStock price movements On February 7, Solid Biosciences (SLDB) closed at $7.19, 67.82% lower than its previous closing price, 5.27% higher than its 52-week low of $6.83, and 86.89% below its
Solid Biosciences crashed Thursday after its experimental gene therapy disappointed in a study of Duchenne muscular dystrophy patients. Sarepta Therapeutics, a rival, saw shares pop.
Sarepta Therapeutics solidified its position as the leader in developing a gene therapy for Duchenne muscular dystrophy following disappointing data from a clinical trial released Thursday.
Holzer & Holzer, LLC is investigating whether certain statements made by Solid Biosciences, Inc. complied with federal securities laws.
Cambridge biotech Solid Biosciences' stock dropped more than 70 percent Thursday after its Duchenne muscular dystrophy drug failed to come close to the effectiveness of its competitor in early tests.
Shares of Solid Biosciences fell 73% in premarket trade Tuesday after the company said preliminary findings from a Phase 1/2 clinical trial of lead candidate SGT-001 found that patients with Duchenne muscular dystrophy (DMD) who were treated with the drug showed low levels of microdystrophin protein expression. DMD is caused by mutations in the dystrophin gene -- people with the mutation can't make dystrophin protein, which is usually present in skeletal and cardiac muscles and helps protect them from injury. SGT-001 is a drug that delivers to the body a synthetic form of the dystrophin gene that codes for a replacement protein called microdystrophin. The six patients in Solid Biosciences' early-phase trial showed low levels of microdystrophin even after being treated, something the company believes can be fixed with higher doses of the drug. "We believe that SGT-001 will be a meaningful treatment for patients with DMD and are confident we have the right approach in place to evaluate its potential at higher doses. We have already begun working to expedite the planned dose escalation strategy outlined in our clinical trial protocol," said Ilan Ganot, co-founder, CEO and president of Solid Biosciences. Shares of the company have declined 17% in the year to date, while the S&P 500 has gained 9%.
Solid Biosciences (SLDB) announced today preliminary findings from IGNITE DMD, the Company’s Phase I/II dose-ascending clinical trial evaluating the safety and efficacy of SGT-001 microdystrophin gene transfer for the treatment of Duchenne muscular dystrophy (DMD). Initial three-month biopsy data showed low levels of microdystrophin protein expression. The Company is currently engaging with the appropriate parties to dose escalate as planned and as soon as possible.
CAMBRIDGE, Mass., Jan. 02, 2019 -- Solid Biosciences Inc. (NASDAQ: SLDB) today announced that Ilan Ganot, Co-Founder, Chief Executive Officer and President of Solid Biosciences.
NEW YORK, Nov. 21, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
On November 13, Solid Biosciences’ (SLDB) stock price closed at $31.94, which represents ~10.48% growth from the close of $28.91 on November 12. On November 13, Solid Biosciences’ stock price increased after it presented its third-quarter financial results.
Two Additional Patients Dosed With SGT-001 Gene Transfer in IGNITE DMD Clinical Trial Company Plans to Report Preliminary Results from IGNITE DMD in the First Quarter of 2019.
CAMBRIDGE, Mass., Nov. 09, 2018 -- Solid Biosciences Inc. (NASDAQ: SLDB) today announced that management will present at the Credit Suisse 27th Annual Healthcare Conference on.
The emerging cell therapy company Orgenesis Inc (ORGS) continues to prove they've got the right stuff, growing their revenue 50% in fiscal Q3 over the previous quarter and 143% compared to the previous year. The company just signed another high-profile Cell Therapy company, Iovance Biotherapeutics (IOVA), as a client, joining Crispr Therapeutics (CRSP) and Adaptimmune (ADAP) among others. As they continue to sign clients, grow revenue, and add global manufacturing capacity, valuation metrics suggest this NASDAQ listing could be substantially undervalued.